Original Article
Full Access
Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias
Dr. P. Piccini,
R. A. Weeks,
D. J. Brooks,
Corresponding Author
Dr. P. Piccini
MRC Cyclotron Unit, Hammersmith Hospital, London, UK
MRC Cyclotron Unit, Hammersmith Hospital, London W12 ONN, UKSearch for more papers by this authorR. A. Weeks
MRC Cyclotron Unit, Hammersmith Hospital, London, UK
Search for more papers by this authorD. J. Brooks
MRC Cyclotron Unit, Hammersmith Hospital, London, UK
Search for more papers by this authorDr. P. Piccini,
R. A. Weeks,
D. J. Brooks,
Corresponding Author
Dr. P. Piccini
MRC Cyclotron Unit, Hammersmith Hospital, London, UK
MRC Cyclotron Unit, Hammersmith Hospital, London W12 ONN, UKSearch for more papers by this authorR. A. Weeks
MRC Cyclotron Unit, Hammersmith Hospital, London, UK
Search for more papers by this authorD. J. Brooks
MRC Cyclotron Unit, Hammersmith Hospital, London, UK
Search for more papers by this authorAbstract
Levodopa-induced dyskinesias remain a major challenge in the therapeutic management of Parkinson's disease (PD). Their etiology is unknown although dysfunction of striatal opioid transmission has been implicated in experimental models of PD. To determine whether the opioid system is involved in human dyskinetic PD, we measured in vivo opioid receptor binding in PD patients with and without levodopa-induced dyskinesias, using positron emission tomography (PET) and the opioid receptor ligand [11C]diprenorphine. Striatal and thalamic/occipital uptake ratios were calculated using a region of interest (ROI) approach. In addition, we used statistical parametric mapping (SPM) and images reflecting the volume of distribution of [11C]diprenorphine to assess changes in cerebral receptor binding on a voxel-by-voxel basis. By using the ROI approach, we found significantly reduced striatal and thalamic opioid binding in dyskinetic, but not in nondyskinetic, PD patients. The SPM approach confirmed reduced availability in these areas and, in addition, showed decreased cingulate and increased prefrontal opioid receptor binding in the dyskinetic patients. Our findings confirm that altered opioid transmission is part of the pathophysiology of levodopa-induced dyskinesias in PD and support further investigation into the role of opioid agents in the management of these involuntary movements.
References
- 1 Boyce S, Rupniak NMJ, Steventon MJ, Iversen SD. Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implication for Parkinson's disease. Neurology 1990; 40: 927–933
- 2 Blanchet P, Bedard PJ, Britton DR, Kebabian JW. Differential effect of selective D1 and D2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine-exposed monkeys. J Pharmacol Exp Ther 1993; 267: 275–279
- 3 Piccini P, Turjanski N, Brooks DJ. PET studies of the striatal dopaminergic system in Parkinson's disease. J Neural Transm 1995; 45: (suppl) 123–131
- 4 Turjanski N, Lees AJ, Brooks DJ. In vivo studies on striatal dopamine D1 and D2 site binding in l-dopa treated Parkinson's disease patients with or without dyskinesia. Neurology (in press)
- 5 Haber SN, Watson SJ. The comparative distribution of enkephalin, dynorphin and substance P in the human globus pallidus and basal forebrain. Neuroscience 1985; 14: 1001–1024
- 6 Austin MC, Kalivas PW. Enkephalinergic and GABAergic modulation of motor activity in the ventral pallidum. J Pharmacol Exp Ther 1990; 252: 1370–1377
- 7 Engberg TM, Susel Z, Kuo S, et al. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res 1991; 552: 113–118
- 8 Taylor MD, De Ceballos ML, Rose S, et al. Effects of unilateral 6-hydroxydopamine lesion and prolonged l-3,4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia. Eur J Pharmacol 1992; 219: 183–192
- 9 Jolkkonen J, Jenner P, Marsden CD. L-Dopa reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP. Mol Brain Res 1995; 32: 297–307
- 10 Luthra SK, Osman S, Turto DR, et al. An automated system based on solid phase extraction and HPLC for the routine determination in plasma of unchanged [11C]deprenyl, [11C]diprenorphine, [11C]flumazenil, [11C]raclopride and [11C]Schering 22390. J Label Comp Radiopharm 1993; 32: 518–520
- 11 Spinks TJ, Jones T, Gilardi M, et al. Physical performance of the latest generation of commercial positron scanner. IEEE Trans Nucl Sci 1988; 35: 721–725
- 12 Jones AKP, Cunningham VJ, Ha-Kawa SK, et al. Quantitation of [11C]diprenorphine cerebral kinetics in man acquired by PET using presaturation, pulse-chase and tracer-only protocols. J Neurosci Methods 1994; 51: 123–134
- 13 Cunningham VJ, Jones T. Spectral analysis of dynamic PET data. J Cereb Blood Flow Metab 1993; 13: 15–23
- 14 Cunningham VJ, Ashburner J, Byrne H, et al. Use of spectral analysis to obtain parametric images from dynamic PET studies. In: K Uemura, ed. Quantification of brain function. Tracer kinetic and image analysis in brain PET. Amsterdam: Elsevier Science, 1993: 101–111
- 15 Tadokoro M, Jones AKP, Cunningham VJ, et al. Parametric images of [11C]diprenorphine binding using spectral analysis of dynamic PET images acquired in 3D. In: K Uemura, NA Lassen, T Jones, I Kanno, eds. Quantification of brain function. Amsterdam: Elsevier Science, 1993: 289–301
- 16 Weeks RA, Cunningham VJ, Piccini P, et al. [11C]Diprenorphine binding in Huntington's disease: a comparison of region of interest analysis with statistical parametric mapping. J Cereb Blood Flow Metab (in press)
- 17 Friston KJ, Holmes AP, Worsley KJ, et al. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Map 1995; 2: 189–210
- 18 Rinne UK, Rinne JK, Rinne JO, et al. Brain enkephalin receptors in Parkinson's disease. J Neural Transm 1983; (suppl 19): 163–171
- 19 Delay-Goyet P, Zajac JM, Javoy-Agid F, et al. Regional distribution of mu, delta and kappa opioid receptors in human brains from controls and parkinsonian subjects. Brain Res 1987; 414: 8–14
- 20 Fernandez A, De Ceballos ML, Jenner P, Marsden CD. Neurotensin, substance P, delta and mu opioid receptors are decreased in basal ganglia of Parkinson's disease patients. Neuroscience 1994; 61: 73–79
- 21 Nisbet AP, Foster OJ, Kingsbury A, et al. Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and Parkinson's disease. Neuroscience 1995; 66: 361–376
- 22 Li SJ, Jiang HK, Stachowiak MS, et al. Influence of nigrostriatal dopaminergic tone on the biosynthesis of dynorphin and enkephalin in rat striatum. Mol Brain Res 1990; 8: 219–225
- 23 Henry B, Crossman AR, Brotchie JM. Opioid peptide involvement in l-dopa-induced dyskinesias: molecular and behavioural studies following long-term treatment in the 6-OHDA-lesioned rat model of Parkinson's disease. Mov Disord 1996; 11 (suppl 1): 61 (Abstract)
- 24 Carey RJ. Naloxone reverses l-dopa induced overstimulation effects in a Parkinson's disease animal model analogue. Life Sci 1991; 48: 1303–1308
- 25 Crossman AR. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesias in Parkinson's disease: implication for future strategies in treatment. Mov Disord 1990; 5: 100–108
- 26 Jackson A, Crossman AR. Experimental choreoathetosis produced by injection of a gamma-aminobutyric acid antagonist into the lentiform nucleus in the monkey. Neurosci Lett 1984; 46: 41–45
- 27 Mitchell IJ, Jackson A, Sambrook MA, Crossman AR. Common neural mechanisms in experimental chorea and hemiballismus in the monkey. Evidence from 2-deoxy-glucose autoradiography. Brain Res 1985; 339: 346–350
- 28 Cuello AC, Paxinos G. Evidence for a long leu-enkephalin striatopallidal pathway in the rat brain. Nature 1978; 271: 178–180
- 29 Maneuf YP, Mitchell IJ, Crossman AR, Brotchie JM. On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus. Exp Neurol 1994; 125: 65–71
- 30 Maneuf YP, Mitchell IJ, Crossman AR, et al. Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease. Brain Res 1995; 683: 102–108
- 31 Hill MP, Brotchie JM. Modulation of glutamate release by kappa opioid agonist in rodent and primate striatum. Eur J Pharmacol 1995; 683: R1–R2
- 32 Henry B, Brotchie JM. Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease. Drugs Ageing 1966; 9: 1–10
- 33 Richards ML, Sadee W. In vivo opiate receptor binding of oripavines to μ, δ and κ sites in rat brain as by an ex vivo labelling method. Eur J Pharmacol 1985; 114: 343–353
- 34 Burn DJ, Rinne JO, Quinn NP, et al. Striatal opioid receptor binding in Parkinson's disease, striatonigral degeneration and Steele-Richardson-Olszewski syndrome. A [11C]diprenorphine PET study. Brain 1995; 118: 951–958
- 35 Ostrowski NL, Pert AGU. Substantia nigra opiate receptors on basal ganglia efferents. Brain Res Bull 1995; 38: 513–523
- 36 Vogt BA, Wiley RG, Jensen EL. Localization of mu and delta opioid receptors to anterior cingulate afferents and projection neurons and input/output model of mu regulation. Exp Neurol 1995; 135: 83–92
- 37 Weeks RA, Turjanski N, Brooks DJ. Tourette's syndrome: a disorder of cingulate and orbitofrontal function? Q J Med 1996; 89: 401–408
- 38 Kurlan R, Majumdar L, Deeley C, et al. A controlled trial of propoxyphene and naltrexone in patients with Tourette's syndrome. Ann Neurol 1991; 30: 19–23
- 39 Stoessl JA, Polanski E, Frydryszak H. The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia. Mov Disord 1993; 8: 445–452
- 40 Nutt JG, Rosin AJ, Eisler T, et al. Effect of an opiate antagonist on movement disorders. Arch Neurol 1978; 35: 810–811
- 41 Trabucchi M, Bassi S, Frattola L. Effect of naloxone on the “on-off” syndrome in patients receiving long-term levodopa therapy. Arch Neurol 1982; 39: 120–121
- 42 Sandyk R, Snider SN. Naloxone treatment of l-dopa-induced dyskinesias in Parkinson's disease. Am J Psychiatry 1986; 143: 118 (Letter)
- 43 Rascol O, Fabre N, Blin O, et al. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Mov Disord 1994; 4: 437–440
Citing Literature
